IL141531A0 - Methods of using and compositions comprising dopamine reuptake inhibitors - Google Patents
Methods of using and compositions comprising dopamine reuptake inhibitorsInfo
- Publication number
- IL141531A0 IL141531A0 IL14153199A IL14153199A IL141531A0 IL 141531 A0 IL141531 A0 IL 141531A0 IL 14153199 A IL14153199 A IL 14153199A IL 14153199 A IL14153199 A IL 14153199A IL 141531 A0 IL141531 A0 IL 141531A0
- Authority
- IL
- Israel
- Prior art keywords
- disorders
- dopamine reuptake
- disorder
- desmethylsibutramine
- didesmethylsibutramine
- Prior art date
Links
- 239000000221 dopamine uptake inhibitor Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 3
- 208000000044 Amnesia Diseases 0.000 abstract 2
- 208000031091 Amnestic disease Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical class C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 abstract 2
- 229960004425 sibutramine Drugs 0.000 abstract 2
- WQSACWZKKZPCHN-AWEZNQCLSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N)CC(C)C)CCC1 WQSACWZKKZPCHN-AWEZNQCLSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010010071 Coma Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000026725 cyclothymic disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000027765 speech disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Information Transfer Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9766598P | 1998-08-24 | 1998-08-24 | |
| US9930698P | 1998-09-02 | 1998-09-02 | |
| US09/372,158 US6331571B1 (en) | 1998-08-24 | 1999-08-11 | Methods of treating and preventing attention deficit disorders |
| PCT/US1999/019167 WO2000010551A2 (en) | 1998-08-24 | 1999-08-23 | Methods of using and compositions comprising dopamine reuptake inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL141531A0 true IL141531A0 (en) | 2002-05-23 |
Family
ID=27378425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14153199A IL141531A0 (en) | 1998-08-24 | 1999-08-23 | Methods of using and compositions comprising dopamine reuptake inhibitors |
| IL141531A IL141531A (en) | 1998-08-24 | 2001-02-20 | Use of a sibutramine metabolite for the manufacture of a medicament for treating attention deficit disorder (add) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL141531A IL141531A (en) | 1998-08-24 | 2001-02-20 | Use of a sibutramine metabolite for the manufacture of a medicament for treating attention deficit disorder (add) |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US6331571B1 (enExample) |
| EP (2) | EP1107746B1 (enExample) |
| JP (1) | JP2002523366A (enExample) |
| KR (3) | KR20080011354A (enExample) |
| CN (1) | CN100415222C (enExample) |
| AT (1) | ATE279184T1 (enExample) |
| AU (2) | AU772303B2 (enExample) |
| CA (1) | CA2341441C (enExample) |
| CZ (1) | CZ2001677A3 (enExample) |
| DE (1) | DE69921157T2 (enExample) |
| DK (1) | DK1107746T3 (enExample) |
| ES (1) | ES2226435T3 (enExample) |
| HU (1) | HUP0103408A3 (enExample) |
| ID (1) | ID28638A (enExample) |
| IL (2) | IL141531A0 (enExample) |
| NO (1) | NO20010943L (enExample) |
| NZ (1) | NZ510193A (enExample) |
| PL (1) | PL200264B1 (enExample) |
| PT (1) | PT1107746E (enExample) |
| WO (1) | WO2000010551A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
| US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
| US6323242B1 (en) * | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| TR200102646T2 (tr) * | 1999-03-19 | 2002-08-21 | Knoll Gmbh | Yeme bozukluklarının tedavi edilmesi. |
| KR100948757B1 (ko) * | 1999-07-01 | 2010-03-23 | 파마시아 앤드 업존 캄파니 엘엘씨 | 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법 |
| US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| WO2002036540A2 (en) * | 2000-11-02 | 2002-05-10 | Torrent Pharmaceuticals Ltd | PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE |
| US20020115727A1 (en) * | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| ATE409475T1 (de) * | 2001-02-20 | 2008-10-15 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
| DE10142666A1 (de) * | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| CN1655787A (zh) * | 2002-05-30 | 2005-08-17 | 神经研究公司 | 治疗慢性疼痛的三单胺再摄取抑制剂 |
| US20040197397A1 (en) * | 2002-08-30 | 2004-10-07 | Watson Pharmaceuticals, Inc. | Drug delivery system for treatment of urinary incontinence |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US20050228052A1 (en) * | 2004-01-29 | 2005-10-13 | Barberich Timothy J | Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US20050267176A1 (en) * | 2004-02-18 | 2005-12-01 | Sepracor Inc. | Dopamine-agonist combination therapy for improving sleep quality |
| US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
| KR100618176B1 (ko) * | 2004-12-02 | 2006-09-01 | 휴먼팜 주식회사 | 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물 |
| EP1828096A2 (en) * | 2004-12-22 | 2007-09-05 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Enantioselective synthesis of a sterically hindered amine |
| KR20060080818A (ko) * | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
| JP2008526836A (ja) * | 2005-01-06 | 2008-07-24 | シージェー チェイルジェダン コーポレーション | シブトラミンの無機酸塩 |
| KR20060080817A (ko) * | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
| KR20060093564A (ko) * | 2005-02-22 | 2006-08-25 | 종근당바이오 주식회사 | 무수 시부트라민 말산염 및 이의 제조 방법 |
| KR100632470B1 (ko) * | 2005-02-25 | 2006-10-12 | 민연식 | 결정성 시부트라민 캄실레이트염과 이의 제조방법 |
| WO2006115770A2 (en) * | 2005-04-22 | 2006-11-02 | Teva Pharmaceuticals Usa, Inc. | Orally disintegrating pharmaceutical tablet formulations of olanzapine |
| WO2006136945A1 (en) * | 2005-06-17 | 2006-12-28 | Pfizer Products Inc. | METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
| EP1996194B1 (en) * | 2006-03-10 | 2011-03-09 | The Research Foundation Of State University Of New York | Homotropanes with central nervous system activity |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| CN101674728A (zh) * | 2007-02-12 | 2010-03-17 | Dmi生物科学公司 | 降低曲马多的副作用 |
| MX2009008491A (es) * | 2007-02-12 | 2010-01-20 | Dmi Biosciences Inc | Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas. |
| WO2010022236A2 (en) * | 2008-08-20 | 2010-02-25 | The University Of Medicine And Dentistry Of New Jersey | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor |
| WO2010093243A1 (en) | 2009-02-12 | 2010-08-19 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
| WO2010126970A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Methods for treating and preventing erectile dysfunction |
| AU2011291506B2 (en) | 2010-08-19 | 2016-07-28 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| NL2022615B1 (en) | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |
| CN113908295B (zh) * | 2021-11-12 | 2023-07-21 | 郑州大学第一附属医院 | 一种阿普唑仑包合物及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3008993A1 (de) | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
| ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| JPS5940638A (ja) | 1982-08-30 | 1984-03-06 | Fuji Photo Film Co Ltd | 直接ポジ用ハロゲン化銀写真乳剤 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| GB8909209D0 (en) | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| EP0554172B1 (en) | 1992-01-28 | 1998-04-29 | Fujitsu Limited | Color surface discharge type plasma display device |
| US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
| JPH08500093A (ja) | 1992-06-23 | 1996-01-09 | セプラコア インコーポレーテッド | 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 |
| AU4542993A (en) | 1992-06-23 | 1994-01-24 | Sepracor, Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
| GB9402641D0 (en) | 1994-02-11 | 1994-04-06 | Boots Co Plc | Therapeutic agents |
| CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| ATE212860T1 (de) | 1994-09-19 | 2002-02-15 | Fujisawa Pharmaceutical Co | Eine neuartige medizinische verwendung eines 5ht 3-antagonisten |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9524681D0 (en) | 1995-12-02 | 1996-01-31 | Knoll Ag | Chemical process |
| DE19632423A1 (de) | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
| GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| GB9619962D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| GB9619961D0 (en) | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| US5795880A (en) | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
-
1999
- 1999-08-11 US US09/372,158 patent/US6331571B1/en not_active Expired - Lifetime
- 1999-08-23 ES ES99945137T patent/ES2226435T3/es not_active Expired - Lifetime
- 1999-08-23 KR KR1020087001197A patent/KR20080011354A/ko not_active Ceased
- 1999-08-23 WO PCT/US1999/019167 patent/WO2000010551A2/en not_active Ceased
- 1999-08-23 NZ NZ510193A patent/NZ510193A/en not_active IP Right Cessation
- 1999-08-23 AT AT99945137T patent/ATE279184T1/de active
- 1999-08-23 DK DK99945137T patent/DK1107746T3/da active
- 1999-08-23 HU HU0103408A patent/HUP0103408A3/hu unknown
- 1999-08-23 EP EP99945137A patent/EP1107746B1/en not_active Expired - Lifetime
- 1999-08-23 CN CNB998124664A patent/CN100415222C/zh not_active Expired - Fee Related
- 1999-08-23 CA CA2341441A patent/CA2341441C/en not_active Expired - Fee Related
- 1999-08-23 IL IL14153199A patent/IL141531A0/xx unknown
- 1999-08-23 KR KR1020067012844A patent/KR100887008B1/ko not_active Expired - Fee Related
- 1999-08-23 ID IDW20010700A patent/ID28638A/id unknown
- 1999-08-23 AU AU57817/99A patent/AU772303B2/en not_active Ceased
- 1999-08-23 PL PL346843A patent/PL200264B1/pl not_active IP Right Cessation
- 1999-08-23 KR KR1020017002288A patent/KR20010085553A/ko not_active Ceased
- 1999-08-23 EP EP04018454A patent/EP1475086A3/en not_active Withdrawn
- 1999-08-23 PT PT99945137T patent/PT1107746E/pt unknown
- 1999-08-23 CZ CZ2001677A patent/CZ2001677A3/cs unknown
- 1999-08-23 DE DE69921157T patent/DE69921157T2/de not_active Expired - Lifetime
- 1999-08-23 JP JP2000565873A patent/JP2002523366A/ja active Pending
-
2001
- 2001-02-20 IL IL141531A patent/IL141531A/en not_active IP Right Cessation
- 2001-02-23 NO NO20010943A patent/NO20010943L/no not_active Application Discontinuation
- 2001-12-04 US US10/000,806 patent/US6538034B2/en not_active Expired - Lifetime
-
2003
- 2003-03-25 US US10/395,298 patent/US7071234B2/en not_active Expired - Fee Related
-
2004
- 2004-03-03 AU AU2004200875A patent/AU2004200875B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL141531A0 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| SI1678172T1 (sl) | AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema | |
| DE122005000044I2 (de) | R-Enantiomer des N-Propargyl-1-Aminoindan zur Behandlung verschiedener Krankheiten und Mesylat, Esylat und Sulfat davon | |
| JP2003524613A5 (enExample) | ||
| CA2352324A1 (en) | Derivatives of (-)-venlafaxine and methods of preparing and using the same | |
| NO975331L (no) | Anvendelse av R-enantiomer av N-propargyl-1-aminoindan salter og sammensetninger derav | |
| RU2009138602A (ru) | Новые производные бензазепина | |
| Tabaddor et al. | Ventricular fluid homovanillic acid and 5‐hydroxyindoleacetic acid concentrations in patients with movement disorders | |
| TWI312679B (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| Koller | Alcoholism in essential tremor | |
| US20040266864A1 (en) | Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram | |
| SI1426355T1 (sl) | Kristali hidoksinorefedrinskega derivata | |
| WO2004077938A3 (en) | Novel chemical entities and methods for their use in treatment of metabolic disorders | |
| TW200635589A (en) | Therapeutic agents | |
| IL142803A0 (en) | Pharmaceutical compositions containing r-tofisopam | |
| AU3342899A (en) | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | |
| JP2004529936A5 (enExample) | ||
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| KR100882925B1 (ko) | 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물 | |
| Gong et al. | Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with a monoamine oxidase inhibitor | |
| Reynolds et al. | Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug | |
| WO2000078765A3 (en) | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | |
| MX2008012212A (es) | Metodos para tratar trastornos cognitivos y otros afines. | |
| Ryder | KETAMINE ENANTIOMERS: COMPARATIVE PHARMACOLOGY AND NEUROCHEMICAL EFFECTS. | |
| Higgins | New therapeutic choices for treating Alzheimer’s disease |